Document is current
Any future updates will be listed below
-
Authors
Zhang, Lanyue https://orcid.org/0000-0002-6798-1320
Omarov, Murad https://orcid.org/0000-0001-6126-8631
Xu, Lingling
deGoma, Emil
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Georgakis, Marios K. https://orcid.org/0000-0003-3507-3659
-
Funding
Funding for this research was provided by:
Fritz Thyssen Stiftung (10.22.2.024MN)
Deutsche Forschungsgemeinschaft (512461526)
Gemeinnützige Hertie-Stiftung (ID P1239935)
The Munich Cluster for Systems Neurolog
- License Information
-
More Information
Article History
Received: 7 February 2025
Accepted: 28 July 2025
First Online: 26 August 2025
Competing interests
: E.d.G. is an employee of Tourmaline Bio. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech/Roche and Novartis; personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk and TenSixteen Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. P.N. is also an advisor to Tourmaline Bio without equity, and was not supported by Tourmaline Bio for this research. M.K.G. reports consulting fees from Tourmaline Bio, Pheiron and Gerson Lehrman Group. The other authors declare no competing interests.
